These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 4574129

  • 41. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host.
    Sterling TR, Gasser RA, Ziegler A.
    Clin Infect Dis; 1996 Jul; 23(1):187-8. PubMed ID: 8816156
    [No Abstract] [Full Text] [Related]

  • 42. [Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999-2001].
    Mujica MT, Finquelievich JL, Jewtuchowicz V, Iovannitti CA.
    Rev Argent Microbiol; 2004 Jul; 36(3):107-12. PubMed ID: 15559191
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Identification and antifungal susceptibility of Candida species isolated from the urine of patients in a university hospital in Brazil.
    Lima GME, Nunes MO, Chang MR, Tsujisaki RAS, Nunes JO, Taira CL, Thomaz DY, Negro GMBD, Mendes RP, Paniago AMM.
    Rev Inst Med Trop Sao Paulo; 2017 Dec 21; 59():e75. PubMed ID: 29267583
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. [Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy].
    Czaika V, Tietz HJ, Schmalreck A, Sterry W, Schultze W.
    Mycoses; 2000 Dec 21; 43 Suppl 2():45-50. PubMed ID: 11291577
    [Abstract] [Full Text] [Related]

  • 51. Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice.
    Rabinovich S, Shaw BD, Bryant T, Donta ST.
    J Infect Dis; 1974 Jul 21; 130(1):28-31. PubMed ID: 4601179
    [No Abstract] [Full Text] [Related]

  • 52. Correlation between in vitro and in vivo activity of antifungal agents against Candida species.
    Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V.
    J Infect Dis; 1994 Aug 21; 170(2):384-9. PubMed ID: 8035024
    [Abstract] [Full Text] [Related]

  • 53. Antifungal susceptibility of 50 Candida isolates from invasive mycoses in Chile.
    Silva V, Alvarado D, Diaz MC.
    Med Mycol; 2004 Jun 21; 42(3):283-5. PubMed ID: 15283244
    [Abstract] [Full Text] [Related]

  • 54. Evaluation of virulence factors and antifungal susceptibility patterns of different Candida species isolated from the female camel (Camelus dromedarius) genital tract.
    Sharifzadeh A, Soltani M, Shokri H.
    Mycoses; 2015 Aug 21; 58(8):478-84. PubMed ID: 26152466
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. [Characteristics of yeast-like fungi of Candida species isolated from patients in the process of treatment with levorin preparations].
    Egorenkova AN, Iarobkova ND.
    Antibiotiki; 1968 Feb 21; 13(2):181-5. PubMed ID: 5667948
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.